The overlap between epilepsy and Alzheimer’s disease and the consequences for treatment

References

• Blocq P, Marinesco G. Sur les lesions et la pathogenie del’epilepsie dite essentielle. La Semaine Medicale. 1892;12:445–446.
   Google Scholar
• Möller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci. 1998;248(3):111–122.
   PubMed Web of Science ®Google Scholar
• Allison RS. The senile brain. A clinical study. London: Edward Arnold; 1962. p. 118.
   Google Scholar
• Fuller SC. Alzheimer’s disease (senium praecox): the report of a case and review of published cases. J Nerv Ment Dis. 1912;39:440–455 and 536–557.
   Google Scholar
• Larner AJ. Solomon Carter Fuller (1872–1953) and the early history of Alzheimer’s disease. Adv Clin Neurosci Rehabil. 2013;12(6):21–22.
   Google Scholar
• Hannah JA. A case of Alzheimer’s disease with neuropathological findings. Cmaj. 1936;35(4):361–366.
   PubMedGoogle Scholar
• Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797–811.
   PubMed Web of Science ®Google Scholar
• Katzman R. Editorial: the prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol. 1976;33(4):217–218.
   PubMedGoogle Scholar
• Sulkava R. Alzheimer’s disease and senile dementia of the Alzheimer type: a comparative study. Acta Neurol Scand. 1982;65(6):636–650.
   PubMed Web of Science ®Google Scholar
• Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology. 1986;36(9):1226–1230.
   PubMed Web of Science ®Google Scholar
• Mendez MF, Catanzaro P, Doss RC, et al. Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994;7(4):230–233.
   PubMedGoogle Scholar
• Romanelli MF, Morris JC, Ashkin K, et al. Advanced Alzheimer’s disease is a risk factor for late-onset seizures. Arch Neurol. 1990;47(8):847–850.
   PubMedGoogle Scholar
• Forsgren L, Bucht G, Eriksson S, et al. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia. 1996;37(3):224–229.
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46(3):727–730.
   PubMed Web of Science ®Google Scholar
• Veall RM. The prevalence of epilepsy among mongols related to age. J Ment Def Res. 1974;18(2):99–106.
   PubMedGoogle Scholar
• Mendez MF, Lim GTH. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20(11):791–803.
   PubMed Web of Science ®Google Scholar
• Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66(4):435–440.
   PubMedGoogle Scholar
• Larner AJ. Epileptic seizures in AD patients. Neuromolecular Med. 2010;12(1):71–77.
   PubMed Web of Science ®Google Scholar
• Friedman D, Honig LS, Scarmeas N. Seizures and epilepsy in Alzheimer’s disease. CNS Neurosci Ther. 2012;18(4):285–294.
   PubMed Web of Science ®Google Scholar
• Miranda DDC, Brucki SMD. Epilepsy in patients with Alzheimer’s disease: a systematic review. Dement Neuropsychol. 2014;8(1):66–71.
   PubMedGoogle Scholar
• Born HA. Seizures in Alzheimer’s disease. Neuroscience. 2015;286:251–263.
   PubMed Web of Science ®Google Scholar
• Horvath A, Szucs A, Barcs G, et al. Epileptic seizures in Alzheimer disease: a review. Alzheimer Dis Assoc Disord. 2016;30(2):186–192.
   PubMed Web of Science ®Google Scholar
• Vossel KA, Tartaglia MC, Nygaard HB, et al. Epileptic activity in Alzheimer’s disease: causes and clinical relevance. Lancet Neurol. 2017;16(4):311–322.
   PubMed Web of Science ®Google Scholar
• Larner AJ. Epileptic seizures in neurodegenerative dementia syndromes. J Neurol Neurosci. 2010;1(1):3.
   Google Scholar
• Cretin B, Philippi N, Bousiges O, et al. Do we know how to diagnose epilepsy early in Alzheimer’s disease? Rev Neurol (Paris). 2017;173(6):374–380.
   PubMed Web of Science ®Google Scholar
• Rao SC, Dove G, Cascino GD, et al. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009;14(1):118–120.
   PubMed Web of Science ®Google Scholar
• Krishnan K, Larner AJ. Concurrent onset of transient epileptic amnesia and Alzheimer’s disease. Eur J Neurol. 2009;16(Suppl3):468(abstract 2386).
   Google Scholar
• Cretin B, Philippi N, Sellal F, et al. Can the syndrome of transient epileptic amnesia be the first feature of Alzheimer’s disease? Seizure. 2014;23(10):918–920.
   PubMed Web of Science ®Google Scholar
• Rabinowicz AL, Starkstein SE, Leiguarda RC, et al. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord. 2000;14(4):231–233.
   PubMed Web of Science ®Google Scholar
• Armon C, Peterson GW, Liwnicz BH. Alzheimer’s disease underlies some cases of complex partial status epilepticus. J Clin Neurophysiol. 2000;17(5):511–518.
   PubMed Web of Science ®Google Scholar
• Chiara C, Giovanni A, Giovanni P, et al. Nonconvulsive seizures and dementia: a case report. Int J Alzheimers Dis. 2011;2011:690305.
   PubMedGoogle Scholar
• Baker J, Libretto T, Henley W, et al. The prevalence and clinical features of epileptic seizures in a memory clinic population. Seizure. 2019. in press.
   PubMed Web of Science ®Google Scholar
• Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70(9):1158–1166.
   PubMed Web of Science ®Google Scholar
• Horvath A, Szucs A, Hidasi Z, et al. Prevalence, semiology, and risk factors of epilepsy in Alzheimer’s disease: an ambulatory EEG study. J Alzheimers Dis. 2018;63(3):1045–1054.
   PubMed Web of Science ®Google Scholar
• Lam AD, Deck G, Goldman A, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer’s disease. Nat Med. 2017;23(6):678–680.
   PubMed Web of Science ®Google Scholar
• Vossel KA, Ranasinghe KG, Beagle AJ, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease. Ann Neurol. 2016;80(6):858–870.
   PubMed Web of Science ®Google Scholar
• Li LM, O’Donoghue MF, Sander JW. Myoclonic epilepsy of late onset in trisomy 21. Arq Neuropsiquiatr. 1995;53(4):792–794.
   PubMed Web of Science ®Google Scholar
• Möller JC, Hamer HM, Oertel WH, et al. Late-onset myoclonic epilepsy in Down’s syndrome (LOMEDS). Seizure. 2001;10(4):303–306.
   PubMed Web of Science ®Google Scholar
• De Simone R, Puig XS, Gélisse P, et al. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer’s disease in Down syndrome. Seizure. 2010;19(7):383–389.
   PubMed Web of Science ®Google Scholar
• Larner AJ. Senile myoclonic epilepsy in Down syndrome. Seizure. 2011;20(6):512.
   PubMed Web of Science ®Google Scholar
• Hommet C, Hureaux R, Barré J, et al. Epileptic seizures in clinically diagnosed Alzheimer’s disease: report from a geriatric medicine population. Aging Clin Exp Res. 2007;19(5):430–431.
   PubMed Web of Science ®Google Scholar
• Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia. 2006;47(5):867–872.
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Honig L, Choi H, et al. Seizures in Alzheimer’s disease: who, when, and how common? Arch Neurol. 2009;66(8):992–997.
   PubMedGoogle Scholar
• Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012;69(3):368–372.
   PubMedGoogle Scholar
• Imfeld P, Bodmer M, Schuerch M, et al. Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case-control analysis. Epilepsia. 2013;54(4):700–707.
   PubMed Web of Science ®Google Scholar
• Beagle AJ, Darwish SM, Ranasinghe KG, et al. Relative incidence of seizures and myoclonus in Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis. 2017;60(1):211–223.
   PubMed Web of Science ®Google Scholar
• Cheng CH, Liu CJ, Ou SM, et al. Incidence and risk of seizures in Alzheimer’s disease: a nationwide population-based cohort study. Epilepsy Res. 2015;115:63–66.
   PubMed Web of Science ®Google Scholar
• Nicastro N, Assal F, Seeck M. From here to epilepsy: the risk of seizure in patients with Alzheimer’s disease. Epileptic Disord. 2016;18(1):1–12.
   PubMed Web of Science ®Google Scholar
• Ziso B, Dixon PA, Marson AG. Epilepsy management in older people: lessons from National Audit of Seizure management in Hospitals (NASH). Seizure. 2017;50:33–37.
   PubMed Web of Science ®Google Scholar
• Puri BK, Ho KW, Singh I. Age of seizure onset in adults with Down’s syndrome. Int J Clin Pract. 2001;55(7):442–444.
   PubMed Web of Science ®Google Scholar
• Lott IT, Doran E, Nguyen VQ, et al. Down syndrome and dementia: seizures and cognitive decline. J Alzheimers Dis. 2012;29(1):177–185.
   PubMed Web of Science ®Google Scholar
• Lozsadi DA, Larner AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;22(2):121–124.
   PubMed Web of Science ®Google Scholar
• Picco A, Archetti S, Ferrara M, et al. Seizures can precede cognitive symptoms in late-onset Alzheimer’s disease. J Alzheimers Dis. 2011;27(4):737–742.
   PubMed Web of Science ®Google Scholar
• Cretin B, Sellal F, Philippi N, et al. Epileptic prodromal Alzheimer’s disease, a retrospective study of 13 new cases: expanding the spectrum of Alzheimer’s disease to an epileptic variant? J Alzheimers Dis. 2016;52(3):1125–1133.
   PubMed Web of Science ®Google Scholar
• DiFrancesco JC, Tremolizzo L, Polonia V, et al. Adult-onset epilepsy in presymptomatic Alzheimer’s disease: a retrospective study. J Alzheimers Dis. 2017;60(4):1267–1274.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA work group under the auspices of the department of health and human service task forces on Alzheimer’s disease. Neurology. 1984;34(7):939–944.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629. [Erratum Lancet Neurol. 2014;13(8):757].
   PubMed Web of Science ®Google Scholar
• Bernardi S, Scaldaferri N, Vanacore N, et al. Seizures in Alzheimer’s disease: a retrospective study of a cohort of outpatients. Epileptic Disord. 2010;12(1):16–21.
   PubMed Web of Science ®Google Scholar
• Rauramaa T, Saxlin A, Lohvansuu K, et al. Epilepsy in neuropathologically verified Alzheimer’s disease. Seizure. 2018;58:9–12.
   PubMed Web of Science ®Google Scholar
• Cortini F, Cantoni C, Villa C. Epileptic seizures in autosomal dominant forms of Alzheimer’s disease. Seizure. 2018;61:4–7.
   PubMed Web of Science ®Google Scholar
• Larner AJ. Presenilin-1 mutation Alzheimer’s disease: a genetic epilepsy syndrome? Epilepsy Behav. 2011;21(1):20–22.
   PubMed Web of Science ®Google Scholar
• Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(4):1143–1154.
   PubMed Web of Science ®Google Scholar
• Cabrejo L, Guyant-Maréchal L, Laquerrière A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129(11):2966–2976.
   PubMed Web of Science ®Google Scholar
• Zarea A, Charbonnier C, Rovelet-Lecrux A, et al. Seizures in dominantly inherited Alzheimer disease. Neurology. 2016;87(9):912–919.
   PubMed Web of Science ®Google Scholar
• Larner AJ. Presenilin-1 mutations in Alzheimer’s disease: an update on genotype-phenotype relationships. J Alzheimers Dis. 2013;37(4):653–659.
   PubMed Web of Science ®Google Scholar
• Vöglein J, Noachtar S, McDade E, et al. Seizures as an early symptom of autosomal dominant Alzheimer’s disease. Neurobiol Aging. 2019;76:18–23.
   PubMed Web of Science ®Google Scholar
• Chin J, Scharfman HE. Shared cognitive and behavioural impairments in epilepsy and Alzheimer’s disease and potential underlying mechanisms. Epilepsy Behav. 2013;26(3):343–351.
   PubMed Web of Science ®Google Scholar
• Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodelling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007;55(5):697–711.
   PubMed Web of Science ®Google Scholar
• Minkeviciene R, Rheims S, Dobszay MB, et al. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29(11):3453–3462.
   PubMed Web of Science ®Google Scholar
• Gschwind T, Lafourcade C, Gfeller T, et al. Contribution of early Alzheimer’s disease-related pathophysiology to the development of acquired epilepsy. Eur J Neurosci. 2018;47(12):1534–1562.
   PubMed Web of Science ®Google Scholar
• Born HA, Kim JY, Savjani RR, et al. Suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzheimer’s disease. J Neurosci. 2014;34(11):3826–3840.
   PubMed Web of Science ®Google Scholar
• Costa C, Romoli M, Liguori C, et al. Alzheimer’s disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiol Aging. 2019;73:61–67.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Goncharoff DK, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33(31):12887–12897.
   PubMed Web of Science ®Google Scholar
• Hoyt CT, Domingo-Fernandez D, Balzer N, et al. A systematic approach for identifying shared mechanisms in epilepsy and its comorbidities. Database (Oxford) 2018 2018 Jan 1.
   Google Scholar
• Johnson EL, Krauss GL, Lee AK, et al. Association between midlife risk factors and late-onset epilepsy: results from the atherosclerosis risk in communities study. JAMA Neurol. 2018;75(11):1375–1382.
   PubMed Web of Science ®Google Scholar
• Marx CE, Trost WT, Shampine LJ, et al. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer’s disease. Biol Psychiatry. 2006;60(12):1287–1294.
   PubMed Web of Science ®Google Scholar
• Meletti S, Lucchi C, Monti G, et al. Low levels of progesterone and derivatives in cerebrospinal fluid of patients affected by status epilepticus. J Neurochem. 2018;147(2):275–284.
   PubMed Web of Science ®Google Scholar
• Ziyatdinova S, Gurevicius K, Kutchiashvili N, et al. Spontaneous epileptiform discharges in a mouse model of Alzheimer’s disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res. 2011;94(1–2):75–85.
   PubMed Web of Science ®Google Scholar
• Ziyatdinova S, Viswanathan J, Hiltunen M, et al. Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer’s disease is not long-lasting after treatment discontinuation. Epilepsy Res. 2015;112(May):43–55.
   PubMed Web of Science ®Google Scholar
• Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J Exp Med. 2008;205(12):2781–2789.
   PubMed Web of Science ®Google Scholar
• Shi JQ, Wang BR, Tian YY, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19(11):871–881.
   PubMed Web of Science ®Google Scholar
• Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2012;109(42):E2895–E2903.
   PubMed Web of Science ®Google Scholar
• Baldelli E, Leo G, Andreoli N, et al. Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment. Neuromolecular Med. 2010;12(3):248–259.
   PubMed Web of Science ®Google Scholar
• Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 1995;6(5):258–263.
   PubMedGoogle Scholar
• Larner AJ, Marson AG. Epileptic seizures in Alzheimer’s disease: another fine MESS? J Alzheimers Dis. 2011;25(3):417–419.
   PubMed Web of Science ®Google Scholar
• Cretin B. Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer’s disease. Expert Opin Pharmacother. 2018;19(11):1201–1209.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853–861.
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77(13):1263–1271.
   PubMed Web of Science ®Google Scholar
• Schnier C, Wilkinson T, Mbizvo G, et al. Association of epilepsy with incident dementia. Poster 089, Association of British Neurologists meeting; 2019 May 21–23. Edinburgh.
   Google Scholar
• Giorgi FS, Guida M, Vergallo A, et al. Treatment of epilepsy in patients with Alzheimer’s disease. Expert Rev Neurother. 2017;17(3):309–318.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN, Wu LY, et al. Treatment of epilepsy for people with Alzheimer’s disease. Cochrane Database Syst Rev. 2018;12:CD011922.
   PubMed Web of Science ®Google Scholar
• Belcastro V, Costa C, Galletti F, et al. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol. 2007;14(10):1176–1178.
   PubMed Web of Science ®Google Scholar
• Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav. 2010;17(4):461–466.
   PubMed Web of Science ®Google Scholar
• Lippa CF, Rosso A, Hepler M, et al. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Demen. 2010;25(2):149–154.
   PubMed Web of Science ®Google Scholar
• Sarkis RA, Dickerson BC, Cole AJ, et al. Clinical and neurophysiologic characteristics of unprovoked seizures in patients diagnosed with dementia. J Neuropsychiatry Clin Neurosci. 2016;28(1):56–61.
   PubMed Web of Science ®Google Scholar
• Brigo F. Selecting the appropriate pharmacotherapy for epilepsy in patients with Alzheimer’s disease. Expert Opin Pharmacother. 2018;19(16):1739–1741.
   PubMed Web of Science ®Google Scholar
• Wieshmann UC, Baker GA. Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register. BMJ Open. 2013;3(3):e002564.
   PubMed Web of Science ®Google Scholar
• Cretin B, Blanc F, Gaultier C, et al. Epileptic amnesic syndrome revealing Alzheimer’s disease. Epilepsy Res. 2012;102(3):206–209.
   PubMed Web of Science ®Google Scholar
• Sierra-Marcos A, Bermejo PE, Manso Calderon R, et al. Lacosamide for epileptic seizures in patients with co-morbidities and unusual presentations of epilepsy. CNS Drugs. 2011;25(Suppl1):17–26.
   PubMed Web of Science ®Google Scholar
• Vonck K, Raedt R, Naulaerts J, et al. Vagus nerve stimulation … 25 years later! What do we know about the effects on cognition? Neurosci Biobehav Rev. 2014;45(Sept):63–71.
   PubMed Web of Science ®Google Scholar
• Aso E, Andres-Benito P, Carmona M, et al. Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of Alzheimer’s disease but plays a minor role in the therapeutic properties of a cannabis-based medicine. J Alzheimers Dis. 2016;51(2):489–500.
   PubMed Web of Science ®Google Scholar
• Larner AJ. Dementia and the health of the nation. In: Severn A, editor. Cognitive changes after surgery in clinical practice. London: Springer; 2018. p. 1–15.
   Google Scholar
• Jiang XW, Lu HY, Xu Z, et al. In silico analyses for key genes and molecular genetic mechanism in epilepsy and Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2018;17(8):608–617.
   PubMed Web of Science ®Google Scholar
• Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414–430.
   PubMed Web of Science ®Google Scholar